OFFRE D'UNE DURÉE LIMITÉE. Obtenez 3 mois à 0,99 $/mois. Profiter de l'offre.
Page de couverture de Prescription for Better Access

Prescription for Better Access

Prescription for Better Access

Auteur(s): Mark Hansan and Dr. Scott Howell
Écouter gratuitement

À propos de cet audio

 With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.© 2025 Prescription for Better Access Mark Hansan and Dr. Scott Howell Hygiène et mode de vie sain Science Sciences biologiques Troubles et maladies
Épisodes
  • IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO

    IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO
    Sep 18 2025
    In this episode, former CMS official Jon Blum reflects on the evolution and impact of the IRA’s drug provisions—from foundational drivers and political trade-offs to how 2026 Part D redesign and the M3P cost-smoothing program are reshaping access. We explore why M3P adoption remains limited, how CMS is monitoring plan behavior around negotiated pricing, and what shrinking standalone Part D options may mean for patients, especially in rural areas. Jon also challenges the “blame game” in Washington—emphasizing the systemic incentives behind each actor—and shares his own prescription for equitably balancing drug affordability, innovation, and policy integrity, including thoughts on MFN and future reform paths.
    Voir plus Voir moins
    Moins d'une minute
  • The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference

    The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference
    Jul 17 2025

    At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.

    • Conference Overview
    • Sarah Emond – ICER
    • John O’Brien – National Pharmaceutical Council
    • Annette Powers – Bristol Myers Squibb
    • Ray Pressburger – Accenture
    • Stuart Altman – Power, Politics and Universal Health Care
    • PBMs
    • 340B Program
    • Copay Maximizers
    • Net Price
    • Lilly Direct
    • Indolent Disease, PFS
    • Concomitant Drug
    • HIV & AZT
    • Orphan Drugs
    • Calquence vs Imbruvica
    • Value-Based Contracts
    • Outcome-Based Contracts
    • Disruptive PBMs
    • CostPlus Drugs
    • Fair Access 2024
    • Drug Rebates
    • Drug Carve-Outs
    • Dynamic Pricing
    • Accelerated Approvals
    • ICER Assessment

    Questions? Email comments@prescriptionforbetteraccess.com.
    Follow us on X, LinkedIn, YouTube, and Threads.
    Voir plus Voir moins
    Moins d'une minute
  • The Domino Effect: 2025 Trends in Specialty Drug Benefits Report

    The Domino Effect: 2025 Trends in Specialty Drug Benefits Report
    May 21 2025

    Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this episode, we unpack PSG’s latest research on how employers and health plans are rethinking specialty strategies amid rising pressure: cost management as a top priority, movement toward rebate alternatives, shifting site of care models, and evolving approaches to affordability and utilization management. Our guests break down where the biggest shifts are happening, what’s still missing, and how smarter benefit design can create better outcomes across the healthcare system.

    • PSG (Pharmaceutical Strategies Group)
    • 2025 Trends in Specialty Drug Benefits Report
    • Specialty Drugs
    • Drug Utilization
    • PBM (Pharmacy Benefit Manager)
    • Copay Assistance (Maximizers & Accumulators)
    • Drug Rebates
    • Drug “Carve Outs”
    • Value-Based Agreements
    • Utilization Management
    • Step Therapy
    • Biosimilars
    • Site-of-Care

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.
    Voir plus Voir moins
    51 min
Pas encore de commentaire